Nonhuman Primate Antibody Resource for Immune Cell Depletion

项目摘要 非人灵长类动物试剂资源（NHPRR）开发重组生物材料，以支持 研究人类疾病的动物模型。在我们的P40奖项中，我们制作和分发 每年约400 g重组蛋白试剂。因此，我们拥有工具、专业知识， 基础设施，以生产重组试剂和广泛分销。最近，冠状病毒 严重急性呼吸道综合征冠状病毒2型（SARS-CoV-2）疾病（COVID）被宣布为大流行， 这促进了新动物模型的发展。不幸的是， COVID样本排除了开发猴的中心之间交换参考血清样本 COVID模型。因此，我们的计划是建立安全的重组猕猴免疫球蛋白参考标准 促进开发和验证用于检测致病性冠状病毒的可靠检测方法， NHP动物模型中的抗病毒抗体。具体而言，这笔补充资金将用于 以下试剂：重组冠状病毒反应性恒河猴单克隆IgG（Aim 1）和NHP血清参考品 标准（目标2）。这些猕猴参考抗体试剂将提高性能和可比性 通过促进血清检测开发、熟练程度培训和 在NPRC进行实验室间性能比较（见支持函）。

Project Summary The Nonhuman Primate Reagent Resource (NHPRR) develops recombinant biological materials to support research with animal models of human diseases. In our parent P40 award, we produce and distribute approximately 400g of recombinant protein reagents per year. Therefore, we have the tools, expertise, and infrastructure to manufacture recombinant reagents and distribute them widely. Very recently, coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID) was declared a pandemic, which prompted the development of new animal models. Unfortunately, the potentially infectious nature of COVID samples has precluded the exchange of reference serum samples among centers developing monkey models of COVID. Thus, our plan is to create safe recombinant reference macaque immunoglobulin standards to facilitate the development and validation of reliable assays for the detection of pathogenic coronaviruses and antiviral antibodies in NHP animal models of COVID. Specifically, this supplement will fund the generation of the following reagents: recombinant coronavirus-reactive rhesus monoclonal IgGs (Aim 1) and NHP serum reference standards (Aim 2). These macaque reference antibody reagents will improve the performance and comparability of antibody-based assays for NHP models by facilitating serum assay development, proficiency training, and inter-laboratory performance comparisons at the NPRCs (see letters of support).